Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Dermatologic 1

Conditions

Carcinoma, Squamous Cell 1Carcinoma, Basal Cell 1

Interventions

Cisplatin 1041Cyclophosphamide 974Carboplatin 954Radiotherapy 893Bevacizumab 847Gemcitabine 817pembrolizumab 760Paclitaxel 740Docetaxel 734Oxaliplatin 706Capecitabine 650Fluorouracil 564Rituximab 559Nivolumab 506Dexamethasone 487Etoposide 468Doxorubicin 458Irinotecan 442Drug Therapy 402Leucovorin 377Cytarabine 342Cetuximab 340Lenalidomide 327Trastuzumab 324Pemetrexed 315durvalumab 295Filgrastim 287Magnetic Resonance Spectroscopy 279Temozolomide 275Prednisone 274

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × OTHER × remetinostat × Clear all
NCT03180528 2021-06-08

Topical Remetinostat in Treating Patient With Cutaneous Basal Cell Cancer

Stanford University

Phase 2 Completed
30 enrolled 10 charts
Dermatologic

Carcinoma, Basal Cell

NCT03875859 2021-05-20

Topical Remetinostat Gel as Neoadjuvant Therapy in Patients With Squamous Cell Carcinoma (SCC)

Stanford University

Phase 2 Terminated
4 enrolled 9 charts
Tumor-Agnostic

Carcinoma, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡